Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Conditions: Lung Cancer

First Posted Date: 2008-02-15

Last Posted Date: 2009-02-09

Lead Sponsor: Yonsei University

Target Recruit Count: 41

Registration Number: NCT00616785

Locations: 🇰🇷
Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: Asparaginase
Drug: dexamethasone
Drug: Etoposide
Drug: cyclophosphamide
Drug: Ifosfamide
Drug: cytarabine
Drug: daunorubicin
Drug: doxorubicin
Drug: mercaptopurine
Drug: Vindesine
Drug: Methotrexate
Drug: prednisone
Drug: thioguanine
Drug: Vincristine

First Posted Date: 2008-02-13

Last Posted Date: 2015-01-14

Lead Sponsor: Associazione Italiana Ematologia Oncologia Pediatrica

Target Recruit Count: 2039

Registration Number: NCT00613457

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Placebo
Drug: ZD6474

First Posted Date: 2008-02-13

Last Posted Date: 2020-02-11

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 74

Registration Number: NCT00613626

Locations: 🇺🇸
Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸
Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States

and more 16 locations

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Drug: vorinostat
Biological: rituximab
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Other: pharmacological study
Other: laboratory biomarker analysis
Genetic: gene expression analysis

First Posted Date: 2008-01-28

Last Posted Date: 2017-05-25

Lead Sponsor: University of Washington

Target Recruit Count: 29

Registration Number: NCT00601718

Locations: 🇺🇸
Puget Sound Oncology Consortium, Seattle, Washington, United States

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Secondary Acute Myeloid Leukemia
Adult Acute Myelomonocytic Leukemia (M4)
Untreated Adult Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)

Interventions: Drug: tipifarnib
Drug: etoposide

First Posted Date: 2008-01-28

Last Posted Date: 2014-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT00602771

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

and more 2 locations

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: carboplatin
Drug: dexamethasone
Drug: etoposide
Drug: ifosfamide
Genetic: polymerase chain reaction
Genetic: western blotting

First Posted Date: 2008-01-18

Last Posted Date: 2020-08-10

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 23

Registration Number: NCT00598169

Locations: 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States

and more 14 locations

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Phase 2

Completed

Conditions: Lymphoma
Diffuse Large Cell Lymphoma

Interventions: Drug: Zevalin
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Drug: Rituximab
Procedure: Stem Cell Transplant

First Posted Date: 2008-01-11

Last Posted Date: 2021-02-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00591630

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: etoposide
Drug: nelfinavir mesylate
Genetic: protein expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: biopsy
Radiation: radiation therapy

First Posted Date: 2008-01-09

Last Posted Date: 2020-04-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 55

Registration Number: NCT00589056

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Infection
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Precancerous Condition
Secondary Myelofibrosis

Interventions: Biological: anti-thymocyte globulin
Drug: fludarabine phosphate
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Drug: sirolimus
Drug: methotrexate
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: hematopoietic stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation

First Posted Date: 2008-01-09

Last Posted Date: 2014-09-10

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 32

Registration Number: NCT00589563

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma

Phase 2

Completed

Conditions: Lymphoma, B-Cell

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: rituximab
Drug: cytarabine
Drug: doxorubicin
Drug: tositumomab

First Posted Date: 2007-12-20

Last Posted Date: 2017-05-30

Lead Sponsor: Duke University

Target Recruit Count: 39

Registration Number: NCT00577629

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy